No­vo Nordisk’s 'se­ma' whips Mer­ck’s di­a­betes drug ri­val in PhI­II as it reach­es for best-in-class rank­ing for GLP-1 group

No­vo Nordisk keeps rack­ing up stel­lar re­sults from its late-stage slate of tri­als test­ing the full po­ten­tial of oral semaglu­tide in treat­ing di­a­betes. And the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER